Keith Blundy

Keith is a member of Quotient’s strategic oversight board representing the Sanger Institute. He has extensive experience in drug discovery, strategy, licensing, and financing.

Keith was CEO of STORM Therapeutics from the company’s formation in 2017 through to IND of its lead candidate in 2022. Prior to STORM, Keith was chief executive of Cancer Research Technology Ltd, the commercial arm of Cancer Research UK (CRT), where he drove the development of CRT to become a global leader in the commercialisation of cancer discoveries. He was instrumental in the launch of the £70m Cancer Research Technology Pioneer Fund in partnership with the European Investment Fund (EIF) and BACIT, developed risk sharing drug discovery alliances with AstraZeneca, Teva (formerly Cephalon), Forma, Merck, and MRCT, negotiated the formation of the CRUK – Medimmune antibody therapeutics laboratory and developed CRT’s geographical reach through establishment of CRT Inc. in Boston and partnership with Cancer Therapeutics Pty in Melbourne, Australia.

Keith received his PhD in Genetics from the John Innes Institute and an MBA from the London Business School. After completing a post-doctoral Fulbright scholarship, Keith spent ten years managing and commercializing agricultural biotechnology programmes before transitioning to healthcare through business development at CRT. He was formerly a director of KuDOS Pharmaceuticals Ltd, Mission Therapeutics, Cancer Therapeutics Pty and Inivata Ltd.